Abiopharma

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

Castle Biosciences - Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

InspireMD Reports First Quarter 2025 Financial Results

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

Brookdale Senior Living Inc. - Brookdale to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Brookdale to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results